Background: A heterocyclic hydrocarbon having a 5, 5-diphenylimidazolidine heterocyclic ring that possesses distinctive fundamental structural characteristics. It is a fused ring of aromatic di-benzene and imidazolidine. The flexible heterocyclic molecules in 5, 5-diphenylimidazolidine that have two nitrogen atoms. The biological activity of the 5, 5-diphenylimidazolidine ring and its derivatives is significant and encouraging. We produce a variety of 4-(chloroethoxy)-3- [2,4-dioxo-5,5-diphenylimidazolidine-1-yl) carbonyl] benzene sulfonic acid and its derivatives in this investigation. In literature survey and molecular docking; it was confirmed that 5, 5-diphenylimidazolidine-2,4-dione gives anticonvulsant effects. The pharmacological samples were examined for their ability to prevent convulsions using the strychnine-induced convulsion method. Materials and Methods: Benzoin; Benzil; Urea; Glacial Acetic Acid; 4- Amino Benzoic Acid; Con. HNO3; Formic Acid; 2- Nitro Aniline; 4- Nitro Aniline; Aniline; Acetyl Chloride; Formic Acid; 4- amino Phenol are used for the synthesis.IR, NMR and MS are used for interpretation. Results: Our research led us to the conclusion that a variety of compounds have strong anticonvulsant properties. The compound 4-(2-chloro-N-(2-phenoxyethyl) aniline)-3-[2,4-dioxo-5,5-diphenylimidazolidine-1-yl) carbonyl] sulfonic acid (SPD5)- (scheme II A); 4-(3-chloro-N-(2-phenoxyethyl)aniline)-3-[2,4-dioxo-5,5-diphenylimidazolidine-1-yl) carbonyl] sulfonic acid (SPD6)- (scheme II A); 4-(2,5-dichloro-N-(2-phenoxyethyl)aniline)- 3-[2,4-dioxo-5,5-diphenylimidazolidine-1-yl) carbonyl] sulfonic acid (SPD7) (scheme II A) and 4-(N-(2-phenoxyethyl)aniline)-3-[2,4-dioxo-5,5-diphenylimidazolidine-1-yl) carbonyl] sulfonic acid (SPD3) (scheme II A) gives strong anti-convulsant effects against phenytoin drug. Conclusion: The title compounds and their derivatives were examined for their ability to treat convulsions. Studies of the relationship between structure and activity revealed that compounds containing 5, 5-diphenylimidazolidine derivatives that have an electron-withdrawing group have higher activity than those that have an electron-donating group.